Abstract Number: 1806 • ACR Convergence 2020
The Association of Interferon-α with Kynurenine/Tryptophan Pathway Activation in Systemic Lupus Erythematosus
Background/Purpose: Type I IFN contributes to SLE pathogenesis and stimulates the kynurenine/tryptophan (KYN/TRP) pathway, producing elevated quinolinic acid (QA) levels relative to kynurenic acid (KA)…Abstract Number: 1823 • ACR Convergence 2020
Mycophenolate Mofetil for Systemic Lupus Erythematosus: Our 20-year Experience
Background/Purpose: Mycophenolate Mofetil (MMF) has been long used in the treatment of systemic lupus Erythematosus (SLE). Despite its proven effectiveness, particularly in the treatment of…Abstract Number: 1840 • ACR Convergence 2020
A Novel Biomarker Identifies Systemic Lupus Erythematous (SLE) Patients Who Benefit from Obexelimab (XmAb®5871) Treatment
Background/Purpose: We previously reported Phase 2 SLE trial results for obexelimab, a CD19-targeted FcγRIIb engager that suppresses B-cell activation [1]. The primary endpoint, which measured…Abstract Number: 0244 • ACR Convergence 2020
What Are the Early versus Late Predictors for Systemic Lupus Erythematosus (SLE) Diagnosis?
Background/Purpose: SLE is clinically heterogenous and its diagnosis is often difficult or delayed. The length of time from symptom onset or from when patients seek…Abstract Number: 0260 • ACR Convergence 2020
Does Higher Quality of Care in SLE Improve Quality of Life?
Background/Purpose: Disease activity, damage and quality of life (QOL) are core outcomes in Systemic lupus erythematosus (SLE). ER visits and hospital admissions (non-routine health care…Abstract Number: 0277 • ACR Convergence 2020
Incidence and Time to Classification of Systemic Lupus Erythematosus by Three Different Classification Criteria
Background/Purpose: Classification criteria are standardized definitions required to identify well defined cohorts of patients for research. In practice they are also used as a framework…Abstract Number: 0295 • ACR Convergence 2020
CCL3L3–null Status May Predispose to Systemic Lupus Erythematosus and Non-scarring Alopecia
Background/Purpose: The correlation between the copy number variation of CCL3L1 and susceptibility to systemic lupus erythematosus (SLE), rheumatoid arthritis, Kawasaki disease, and HIV infection has…Abstract Number: 0441 • ACR Convergence 2020
Use of an Integrated Care Management Program to Uncover and Address Social Determinants of Health for Individuals with Lupus
Background/Purpose: The burden of systemic lupus erythematosus (SLE) falls disproportionately on racial/ethnic minorities and individuals of lower socioeconomic status who often receive fragmented, inconsistent care.…Abstract Number: 0582 • ACR Convergence 2020
Mortality and Cost of Hospitalization: Do Hospitals Caring for More SLE Patients Perform Better?
Background/Purpose: Individuals with systemic lupus erythematosus (SLE) have an increased risk of hospitalization throughout their lifetime, potentially leading to higher patient mortality and healthcare costs.…Abstract Number: 0843 • ACR Convergence 2020
Rab4A Activation Predisposes to Hepatitis in Spontaneous and Pristane-Induced Mouse Models of Systemic Lupus Erythematosus
Background/Purpose: HRES-1/Rab4 or Rab4A, a GTPase responsible for mitochondrial oxidative stress1 and activation of the mechanistic target of rapamycin2, is overexpressed in T cells of…Abstract Number: 0862 • ACR Convergence 2020
Voclosporin Does Not Decrease Mycophenolic Acid Concentrations in Patients with SLE
Background/Purpose: Voclosporin (VCS) is a novel calcineurin inhibitor, structurally similar to cyclosporine A (CsA). In a Phase 3 clinical trial in patients with active lupus…Abstract Number: 0976 • ACR Convergence 2020
Kidney-infiltrating T Cells in Murine Lupus Nephritis Exhibit Transcriptional Heterogeneity and Oligoclonal Expansion
Background/Purpose: Lupus nephritis (LN) is a hallmark of SLE, affecting 50-60% of patients within 10 years of diagnosis. Current treatments for LN have suboptimal response…Abstract Number: 1022 • ACR Convergence 2020
Declining In-hospital Mortality Gap in Lupus Compared to Non-lupus Hospitalizations: A National Study
Background/Purpose: Lupus is a serious, multi-system autoimmune disease that affects young people. Mortality is increased by over 2-3 fold compared to the general population. Time-trends…Abstract Number: 1259 • ACR Convergence 2020
The Impact of Antimalarial Agents on Traditional and Non-traditional Cardiovascular Markers in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis
Background/Purpose: Cardiovascular morbidity and mortality is a well-established problem in patients with systemic lupus erythematosus (SLE). Hydroxychloroquine (HCQ) has been seen as a potential atheroprotective…Abstract Number: 1276 • ACR Convergence 2020
Using Classification and Regression Tree Analysis to Assess the Construct Validity of the Automated Neuropsychological Assessment Metrics in the Assessment of Cognitive Impairment in SLE Compared to the ACR Neuropsychological Battery
Background/Purpose: Cognitive impairment (CI) is common in systemic lupus erythematosus (SLE) patients, however there is no standard screening tool available. The American College of Rheumatology…
- « Previous Page
- 1
- …
- 122
- 123
- 124
- 125
- 126
- …
- 150
- Next Page »